SCHEMBL268480

SCHEMBL268480

CCOC(=O)c1c(NC(=O)c2cccc(CN(CC)CC)c2)sc(C=O)c1C

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.53
MAPT P10636 11/20 0.52
NPSR1 Q6W5P4 1/20 0.52
KDM4E B2RXH2 6/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
RCE1 Q9Y256 1/20 0.49
ALDH1A1 P00352 9/20 0.48
HPGD P15428 6/20 0.48
MEP1B Q16820 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.42
RAD52 P43351 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267793 0.81 MEN1 (0.49) SLC2A1MAPTNPSR1KDM4EMEN1
SCHEMBL266070 0.80 MEP1B (0.50) SLC2A1MAPTNPSR1KDM4EMEN1
SCHEMBL11637419 0.73 ALDH1A1 (0.68) MAPTNPSR1KDM4EMEN1KMT2A
SCHEMBL265706 0.72 MAPT (0.61) MAPTNPSR1KDM4EMEN1KMT2A
SCHEMBL265899 0.71 MAPT (0.61) MAPTNPSR1KDM4EALDH1A1HPGD
SCHEMBL266185 0.71 MAPT (0.59) MAPTNPSR1KDM4EMEN1KMT2A
SCHEMBL268309 0.70 RAB9A (0.42) MAPTNPSR1KDM4EMEN1KMT2A
SCHEMBL11376733 0.70 ALDH1A1 (0.77) MAPTNPSR1KDM4EMEN1KMT2A
SCHEMBL31700686 0.69 ALDH1A1 (0.64) MAPTNPSR1KDM4EMEN1KMT2A
SCHEMBL16312398 0.69 SLC2A1 (1.00) SLC2A1MAPTNPSR1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC2A1 34/4885MAPT 4195/4885NPSR1 390/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC2A1 47/4885MAPT 4648/4885NPSR1 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.